LT2976361T - Humanizuoti antikūnai prieš receptorių cd134 (ox40) ir jų naudojimas - Google Patents

Humanizuoti antikūnai prieš receptorių cd134 (ox40) ir jų naudojimas

Info

Publication number
LT2976361T
LT2976361T LTEP14715138.5T LT14715138T LT2976361T LT 2976361 T LT2976361 T LT 2976361T LT 14715138 T LT14715138 T LT 14715138T LT 2976361 T LT2976361 T LT 2976361T
Authority
LT
Lithuania
Prior art keywords
antibodies
humanized anti
humanized
Prior art date
Application number
LTEP14715138.5T
Other languages
English (en)
Inventor
Petrus Johannes Simons
Louis Boon
Jinquan Luo
Randall Brezski
Monica GOLDBERG
Original Assignee
Biocerox Products B.V.
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47891522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2976361(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocerox Products B.V., Janssen Pharmaceuticals, Inc. filed Critical Biocerox Products B.V.
Publication of LT2976361T publication Critical patent/LT2976361T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEP14715138.5T 2013-03-18 2014-03-18 Humanizuoti antikūnai prieš receptorių cd134 (ox40) ir jų naudojimas LT2976361T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13159794 2013-03-18
PCT/NL2014/050162 WO2014148895A1 (en) 2013-03-18 2014-03-18 Humanized anti-cd134 (ox40) antibodies and uses thereof

Publications (1)

Publication Number Publication Date
LT2976361T true LT2976361T (lt) 2018-10-25

Family

ID=47891522

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14715138.5T LT2976361T (lt) 2013-03-18 2014-03-18 Humanizuoti antikūnai prieš receptorių cd134 (ox40) ir jų naudojimas

Country Status (33)

Country Link
US (3) US9790281B2 (lt)
EP (2) EP3409690A1 (lt)
JP (1) JP2016515544A (lt)
KR (1) KR20160006168A (lt)
CN (1) CN105229032A (lt)
AU (2) AU2014238546C1 (lt)
BR (1) BR112015023862A2 (lt)
CA (1) CA2907436A1 (lt)
CL (2) CL2015002793A1 (lt)
CR (1) CR20150498A (lt)
CY (1) CY1120752T1 (lt)
DK (1) DK2976361T3 (lt)
EA (1) EA201591495A1 (lt)
ES (1) ES2687282T3 (lt)
HK (1) HK1215035A1 (lt)
HR (1) HRP20181478T1 (lt)
HU (1) HUE040234T2 (lt)
IL (1) IL241701A0 (lt)
LT (1) LT2976361T (lt)
MD (2) MD20180107A2 (lt)
MX (2) MX2015013288A (lt)
NZ (1) NZ712903A (lt)
PE (1) PE20160690A1 (lt)
PH (1) PH12015502185A1 (lt)
PL (1) PL2976361T3 (lt)
PT (1) PT2976361T (lt)
RS (1) RS57840B1 (lt)
SG (2) SG10201708048XA (lt)
SI (1) SI2976361T1 (lt)
SM (1) SMT201800503T1 (lt)
UA (1) UA119319C2 (lt)
WO (1) WO2014148895A1 (lt)
ZA (1) ZA201507021B (lt)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
WO2014151763A1 (en) 2013-03-14 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting donor-specific antibodies and systems for practicing the same
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CA2966523A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
WO2016073380A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
US20160152720A1 (en) 2014-11-06 2016-06-02 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
SI3242890T1 (sl) * 2015-01-08 2020-01-31 BioNTech SE Agonistična sredstva, ki vežejo receptorje TNF
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
KR20180002653A (ko) 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
US10287346B2 (en) * 2015-04-28 2019-05-14 Mitsubishi Tanabe Pharma Corporation RGMa binding protein and use thereof
SG11201708804WA (en) * 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
DK3303396T5 (da) * 2015-05-29 2024-10-07 Bristol Myers Squibb Co Antistoffer mod ox40 og anvendelser deraf
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
WO2017063162A1 (zh) * 2015-10-15 2017-04-20 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
US10527613B2 (en) * 2015-11-10 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Biomarker detection methods and systems and kits for practicing same
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
KR20180098671A (ko) 2016-01-11 2018-09-04 인히브릭스, 인크. 다가 및 다중특이적 ox40-결합 융합 단백질
ES2985566T3 (es) * 2016-03-04 2024-11-06 Univ Rockefeller Anticuerpos contra CD40 con actividad agonista mejorada
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
EP3470424B1 (en) * 2016-06-08 2025-04-23 Shanghai Jiao Tong University School of Medicine Sequence of antibody heavy chain constant region for enhancing agonist antibody activity
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018031400A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
WO2018031258A1 (en) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US20190276549A1 (en) 2016-11-01 2019-09-12 Genmab B.V. Polypeptide variants and uses thereof
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
BR112019012328A2 (pt) * 2016-12-15 2019-11-19 Abbvie Biotherapeutics Inc anticorpos anti-ox40 e seus usos
US20200347143A1 (en) * 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
MX2019007963A (es) 2017-01-06 2019-10-21 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumor (til) con agonistas de la superfamilia de recptor de factor de necrosis tumoral (tnfrsf) y combinaciones terapeuticas de til- y agonistas de tnfrsf.
EP3571230A4 (en) 2017-01-20 2020-12-16 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DELETION OF CD137 + CELLS
EP3580233A1 (en) 2017-02-10 2019-12-18 Genmab B.V. Polypeptide variants and uses thereof
CN108623686A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
CN113603780B (zh) * 2017-03-28 2022-07-01 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
JP7089149B2 (ja) 2017-07-31 2022-06-22 ミツミ電機株式会社 レンズ駆動装置、カメラモジュール、およびカメラ搭載装置
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
JP7250766B2 (ja) * 2017-08-25 2023-04-03 ヤンセン バイオテツク，インコーポレーテツド ＦＣγＲＩＩ結合フィブロネクチンＩＩＩ型ドメイン、それらのコンジュゲート、及びそれらを含む多重特異性分子
JP2021501801A (ja) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
CR20200251A (es) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Expansión de til de aspirados con aguja fina y biopsias por punción
EP3713958A4 (en) * 2017-11-24 2021-11-03 Eucure (Beijing) Biopharma Co., Ltd ANTI-OX40 ANTIBODIES AND USES THEREOF
JP7057492B2 (ja) 2017-12-28 2022-04-20 ミツミ電機株式会社 レンズ駆動装置、カメラモジュール、及びカメラ搭載装置
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN111393529B (zh) * 2018-01-29 2022-02-22 康源博创生物科技(北京)有限公司 与ox40l非竞争结合的抗ox40抗体
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
CN120943884A (zh) 2018-03-27 2025-11-14 百时美施贵宝公司 使用紫外线信号实时监测滴度
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
TWI831778B (zh) 2018-05-11 2024-02-11 澳門商同潤澳門一人有限公司 抗ox40的全人抗體及其製備方法和用途
BR112020023746A2 (pt) 2018-05-23 2021-02-17 Beigene, Ltd. anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
WO2020036867A1 (en) 2018-08-13 2020-02-20 Inhibrx, Inc. Ox40-binding polypeptides and uses thereof
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
IL281423B2 (en) 2018-09-20 2024-08-01 Iovance Biotherapeutics Inc Expansion of TILS from cryopreserved tumor samples
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
JP7854297B2 (ja) 2018-11-05 2026-05-01 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
US12611427B2 (en) 2018-11-05 2026-04-28 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
MY210603A (en) 2018-11-05 2025-10-01 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020119793A1 (en) * 2018-12-14 2020-06-18 Wuxi Biologics (Shanghai) Co., Ltd. Humanized antibodies against ox40, method for preparing the same, and use thereof
CA3123392A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
WO2020142626A1 (en) * 2019-01-04 2020-07-09 Gigagen, Inc. Anti-ox40 binding proteins and methods of use thereof
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
US20220177841A1 (en) 2019-03-29 2022-06-09 Myst Therapeutics Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
KR20220012292A (ko) 2019-05-23 2022-02-03 브리스톨-마이어스 스큅 컴퍼니 세포 배양 배지를 모니터링하는 방법
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
CN110172090B (zh) * 2019-06-03 2020-04-03 中山标佳生物科技有限公司 Cd134单克隆抗体及其制备方法和癌症治疗中的应用
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
BR112022009147A2 (pt) * 2019-11-21 2022-07-26 Beigene Ltd Métodos de tratamento do câncer e métodos para aumentar, potencializar ou estimular uma resposta ou função imune
JP2023503031A (ja) * 2019-11-21 2023-01-26 ベイジーン（ベイジン）カンパニー リミテッド 化学療法剤との組合せでの抗ｏｘ４０抗体による癌治療の方法
US20230011916A1 (en) * 2019-11-21 2023-01-12 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors
JP2023503399A (ja) * 2019-11-21 2023-01-30 ベイジーン リミテッド 抗ｔｉｍ３抗体と組み合わせて抗ｏｘ４０抗体を用いるがんを治療する方法
US20230002500A1 (en) * 2019-11-21 2023-01-05 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
EP4061421A4 (en) * 2019-11-21 2024-05-15 BeiGene, Ltd. Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
US20230032934A1 (en) 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
IL293471A (en) 2019-12-17 2022-08-01 Amgen Inc Dual interleukin-2 / tnf receptor agonist for use in medicine
CN113045655A (zh) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
EP4512828A3 (en) 2020-02-27 2025-05-14 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN111518209B (zh) * 2020-05-09 2023-07-25 郑州航空港百桥生物科技有限公司 特异性结合人ox40的单克隆抗体及其应用
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
CN116406369A (zh) 2020-10-05 2023-07-07 百时美施贵宝公司 用于浓缩蛋白质的方法
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
EP4259164A1 (en) 2020-12-11 2023-10-18 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
EP4288455A1 (en) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same
JP2024512029A (ja) 2021-03-25 2024-03-18 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CA3215830A1 (en) 2021-04-19 2022-10-27 Rafael CUBAS Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
US20240182593A1 (en) * 2021-05-27 2024-06-06 Yuhan Corporation Ox40 agonist and use thereof
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
JP2024527961A (ja) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
CA3243416A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS
JP2025509274A (ja) 2022-03-09 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー 治療用タンパク質の一過性発現
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
KR20250022071A (ko) 2022-06-02 2025-02-14 브리스톨-마이어스 스큅 컴퍼니 항체 조성물 및 이의 이용 방법
US20260021181A1 (en) 2022-08-01 2026-01-22 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US5591629A (en) 1994-04-29 1997-01-07 Mayo Foundation For Medical Education & Research Monoclonal antibodies which promote central nervous system remyelination
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5504004A (en) 1994-12-20 1996-04-02 Michigan Biotechnology Institute Process for making succinic acid, microorganisms for use in the process and methods of obtaining the microorganisms
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2308565A1 (en) 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
AP1261A (en) 1998-02-24 2004-03-19 Sisters Of Providence In Oregon Composition containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response.
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
CA2573293A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CA2585776A1 (en) 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
WO2006055697A2 (en) 2004-11-17 2006-05-26 Board Of Regents, The University Of Texas System Cancer immunotherapy incorporating p53
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7189097B2 (en) 2005-02-11 2007-03-13 Winchester Electronics Corporation Snap lock connector
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
JP2008542354A (ja) 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
JP5256042B2 (ja) 2005-11-22 2013-08-07 インサイト・コーポレイション 癌の処置のための併用療法
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US20070255631A1 (en) 2005-11-28 2007-11-01 Douglas Schmidt Product catalog management system and method
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
US20110028688A1 (en) 2006-06-21 2011-02-03 Genentech, Inc. Crystal structure of ox40l and ox40l complexed with ox40 receptor
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
KR20100014588A (ko) 2007-02-27 2010-02-10 제넨테크, 인크. 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
CN101293924A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
PT2594590E (pt) 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US8137933B2 (en) 2008-11-12 2012-03-20 Schering Corporation Mammalian expression vector pUHAB
NZ594315A (en) * 2009-02-17 2013-05-31 Ucb Pharma Sa Antibody molecules having specificity for human ox40
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2010129917A2 (en) * 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
WO2011031801A2 (en) 2009-09-08 2011-03-17 Aerovironment, Inc. Electric vehicle simulator and analyzer (evsa) for electric vehicle supply equipment
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
CA2809089C (en) * 2010-08-23 2018-12-18 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
JP5925307B2 (ja) 2011-06-30 2016-05-25 オーエフエス ファイテル，エルエルシー １５５０ｎｍの波長範囲における使用のためのファイバストレッチャモジュール
WO2013008171A1 (en) * 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
CA2845810C (en) * 2011-08-23 2017-03-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
SG11201607969XA (en) 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CA2966523A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Assays for detecting t cell immune subsets and methods of use thereof
WO2016073380A1 (en) 2014-11-03 2016-05-12 Genentech, Inc. Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
US20160152720A1 (en) 2014-11-06 2016-06-02 Genentech, Inc. Combination therapy comprising ox40 binding agonists and tigit inhibitors
SG10201807625PA (en) 2014-11-17 2018-10-30 Genentech Inc Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
KR20180002653A (ko) 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions

Also Published As

Publication number Publication date
WO2014148895A1 (en) 2014-09-25
AU2014238546B2 (en) 2018-10-18
EP2976361A1 (en) 2016-01-27
CN105229032A (zh) 2016-01-06
US20140377284A1 (en) 2014-12-25
KR20160006168A (ko) 2016-01-18
ZA201507021B (en) 2016-11-30
CL2015002793A1 (es) 2016-09-23
NZ712903A (en) 2018-07-27
SI2976361T1 (sl) 2018-11-30
UA119319C2 (uk) 2019-06-10
HRP20181478T1 (hr) 2018-11-02
JP2016515544A (ja) 2016-05-30
BR112015023862A2 (pt) 2017-10-24
US10273307B2 (en) 2019-04-30
CR20150498A (es) 2016-03-30
MX2019004649A (es) 2019-08-05
RS57840B1 (sr) 2018-12-31
EA201591495A1 (ru) 2016-05-31
HUE040234T2 (hu) 2019-02-28
CA2907436A1 (en) 2014-09-25
SG11201507781VA (en) 2015-10-29
US9790281B2 (en) 2017-10-17
PT2976361T (pt) 2018-10-19
SG10201708048XA (en) 2017-10-30
SMT201800503T1 (it) 2018-11-09
AU2014238546C1 (en) 2019-01-17
MD20180107A2 (ro) 2019-06-30
AU2019200164A1 (en) 2019-01-31
MD20150102A2 (ro) 2016-02-29
HK1215035A1 (zh) 2016-08-12
MD4633B1 (ro) 2019-06-30
EP2976361B1 (en) 2018-07-18
AU2014238546A1 (en) 2015-10-01
PE20160690A1 (es) 2016-08-14
IL241701A0 (en) 2015-11-30
MX2015013288A (es) 2016-04-07
EP3409690A1 (en) 2018-12-05
CL2018003807A1 (es) 2019-03-08
US20190202928A1 (en) 2019-07-04
PH12015502185A1 (en) 2016-01-25
ES2687282T3 (es) 2018-10-24
CY1120752T1 (el) 2019-12-11
PL2976361T3 (pl) 2018-12-31
DK2976361T3 (en) 2018-10-01
US20170369586A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
ZA201507021B (en) Humanized anti-cd134 (ox40) antibodies and uses thereof
IL261743B (en) and their uses 33–il antibodies against
IL261547B (en) Antibodies against pesidine and their uses
IL245040B (en) Antibodies against pdgfr-beta and their uses
IL243974B (en) Antibodies against –prlr and uses
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
IL246287A0 (en) Fabs antibodies one by one and their uses
HUE052487T2 (hu) Anti-PD-1 antitest és annak alkalmazása
EP3066470A4 (en) Humanized anti-ceacam5 antibody and uses thereof
SG10201709715RA (en) Anti-b7-h5 antibodies and their uses
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
SG11201602760YA (en) Monoclonal olfml-3 antibodies and uses thereof
EP3066122A4 (en) Pre-haptoglobin-2 monoclonal antibodies and uses thereof